Tumor Marker Carbohydrate Antigen 50(CA50) detection kit for Fully Automatic Immunoassay Analyzer IVD Reagents
Home » Products » Diagnostic Reagents » Tumor Marker Carbohydrate Antigen 50(CA50) detection kit for Fully Automatic Immunoassay Analyzer IVD Reagents


Tumor Marker Carbohydrate Antigen 50(CA50) detection kit for Fully Automatic Immunoassay Analyzer IVD Reagents

CA50 is a kind of carbohydrate antigens with sialic acid lipid and glycoprotein sialic acid as the
main components. It is non-organ-specific and a broad-spectrum tumor marker, which is widely in
the pancreas, gallbladder, liver, stomach, colorectal rectum, bladder, and uterus. It does not exist in
normal tissues. When the cells occur malignant transformation, glycosylation conversion enzyme
is inactivated and some invertase has been activated, resulting in cell surface glycosylation
structural changes and forming CA50.
  • CA50

  • Zecen

  • DR1017

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button


The kit has been designed for the quantitative determination of Carbohydrate Antigen 50 (CA50) in  human serum. 

The method can be used for samples over the range of 1.0~140.0 U/mL

Cancer antigen 50 (CA50) is a glycolipid that is similar to the tumor marker CA19-9; however, CA50 antibodies recognize both the fucosyl form of sialylated Lewis(a) carbohydrate moiety and sialylated Lewis(a) moiety. CA50 is not organ-specific and elevated levels are seen in various conditions such as colitis, pancreatitis, pneumonia, and cancers, especially gastrointestinal cancers (e.g., pancreatic, stomach, hepatic, and colorectal cancers). It can be used as a marker for detecting gastrointestinal cancers, specifically pancreatic and colon cancer. Diagnostic assays for CA50 are based on the antibody sandwich principle using ELISA or CLIA.

Cancer-associated carbohydrate antigen 50 (CA50) is a ganglioside glycoprotein and is a biomarker for the diagnosis and prognosis of gastrointestinal malignancies, especially of pancreatic and colorectal cancers .

The expression level of CA50 has been measured for pancreatic and colorectal cancers and also for other cancers such as breast, lung, renal, prostatic, and ovarian cancers [6]. In addition, it can distinguish the patients of benign disease of atrophic gastritis, pancreatitis, ulcerative colitis, pneumonia, cirrhosis, and autoimmune diseases from healthy persons . The monoclonal antibody that defines CA50 reacts with both the afucosyl form of sialylated Lewis A carbohydrate moiety and sialylated Lewis A moiety on the cancer cell surface . CA50 epitope is assumed to be similar to CA19-9 epitope (sialyl-Lewis A). In fact, both CA19-9 and CA50 are valuable markers for the differentiation of pancreatic cancer from benign diseases of the pancreatobiliary tract . However, in contrast to the limited expression of CA 19-9 in gastrointestinal malignancy, high CA50 levels can also be seen in malignant tumors outside the digestive tract.



Zecen Biotech CO., LTD. founded in 2011, is a leading Chinese diagnostics manufacturer specializing in in-vitro diagnostics devices and reagents.
Leave a Message




Tel: +86-17751649333
Phone: +86-523-86817711
Add: Building G62, Phase 4 Plant, China Medical City, Taizhou City, Jiangsu Province
​Copyright © 2023 Zecen Biotech CO., LTD. All rights reserved. | Sitemap | Privacy Policy | Supported by leadong.com